Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INF904 in chronic spontaneous urticaria and hidradenitis suppurativa
NCT06555328Phase 2Terminated
- Sponsor
- InflaRx
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of izicopan in chronic spontaneous urticaria (CSU), hidradenitis suppurativa (HS), sponsored by InflaRx. Started Jan 2025; status: terminated.
02
Drugs
izicopan
03
Conditions
chronic spontaneous urticaria (CSU)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06555328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555328.